Trung Huynh
Stock Analyst at UBS
(4.40)
# 395
Out of 4,416 analysts
25
Total ratings
63.16%
Success rate
16.81%
Average return
Main Sectors:
Top Industries:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Initiates: Buy | $46 | $26.08 | +76.38% | 1 | Feb 27, 2024 | |
| BMY Bristol-Myers Squibb Company | Assumes: Neutral | $70 → $60 | $44.04 | +36.24% | 3 | Oct 20, 2023 | |
| LLY Eli Lilly | Assumes: Buy | $612 → $710 | $777.77 | -8.71% | 7 | Oct 20, 2023 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $170 → $175 | $148.72 | +17.67% | 2 | Jul 21, 2023 | |
| AMGN Amgen | Maintains: Outperform | $220 → $200 | $300.30 | -33.40% | 3 | Jul 12, 2023 | |
| PFE Pfizer | Downgrades: Neutral | $47 → $40 | $27.77 | +44.04% | 4 | Jun 29, 2023 | |
| MRK Merck & Co. | Maintains: Outperform | $125 → $126 | $130.38 | -3.36% | 3 | Mar 7, 2023 | |
| ABBV AbbVie | Initiates: Outperform | $170 | $162.55 | +4.58% | 1 | Nov 18, 2022 | |
| GRFS Grifols | Upgrades: Outperform | n/a | $6.80 | - | 1 | Mar 23, 2021 |
Insmed
Feb 27, 2024
Initiates: Buy
Price Target: $46
Current: $26.08
Upside: +76.38%
Bristol-Myers Squibb Company
Oct 20, 2023
Assumes: Neutral
Price Target: $70 → $60
Current: $44.04
Upside: +36.24%
Eli Lilly
Oct 20, 2023
Assumes: Buy
Price Target: $612 → $710
Current: $777.77
Upside: -8.71%
Johnson & Johnson
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $148.72
Upside: +17.67%
Amgen
Jul 12, 2023
Maintains: Outperform
Price Target: $220 → $200
Current: $300.30
Upside: -33.40%
Pfizer
Jun 29, 2023
Downgrades: Neutral
Price Target: $47 → $40
Current: $27.77
Upside: +44.04%
Merck & Co.
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $130.38
Upside: -3.36%
AbbVie
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $162.55
Upside: +4.58%
Grifols
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $6.80
Upside: -